MOATAZEDI DAVID — SEC insider filings
SEC reporting owner CIK 1700836. 38 insider filings on record with FilingPulse; latest filed 2026-09-04.
Transaction summary — filings shown
Covers all 38 filings on record, filed 2021-01-26 to 2026-09-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 10,000 shares, $16,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 30 legs across 25 filings — 1,537,273 shares, $16,946,869 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 29.
- Largest priced transaction: sale of 175,940 shares @ $12.59 ($2,214,486) in Evolus, Inc., filed 2024-06-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) | See Remarks, Director | 33 | — | 30 legs · 1,537,273 sh · $16,946,869 | 24 |
| BIOMERICA INC (BMRA) | Director | 5 | 1 leg · 10,000 sh · $16,000 | — | 5 |
Insider filings — MOATAZEDI DAVID
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-04 | 4 | Evolus, Inc. (EOLS) | Sale (S): 105,108 @ $9.04 | EDGAR |
| 2026-08-27 | 4 | BIOMERICA INC (BMRA) | Purchase (P): 10,000 @ $1.60 | EDGAR |
| 2026-03-20 | 4 | Evolus, Inc. (EOLS) | Sale (S): 13,669 @ $4.75 | EDGAR |
| 2026-03-18 | 4 | Evolus, Inc. (EOLS) | Option exercise (M): 67,489 @ $0 · Sale (S): 116,720 @ $4.89 · Option exercise (M): 67,489 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 313,212 @ $0 · Grant/award (A): 626,424 (derivative) @ $0 · Grant/award (A): 457,541 (derivative) @ $0 | EDGAR |
| 2025-12-31 | 4 | BIOMERICA INC (BMRA) | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-12-29 | 4 | Evolus, Inc. (EOLS) | Sale (S): 10,539 @ $7.15 | EDGAR |
| 2025-06-16 | 4 | Evolus, Inc. (EOLS) | Sale (S): 111,323 @ $10.05 · Sale (S): 16,582 @ $9.89 | EDGAR |
| 2025-05-14 | 4 | Evolus, Inc. (EOLS) | Sale (S): 15,787 @ $9.87 | EDGAR |
| 2025-03-28 | 4 | Evolus, Inc. (EOLS) | Sale (S): 6,251 @ $12.40 | EDGAR |
| 2025-03-20 | 4 | Evolus, Inc. (EOLS) | Sale (S): 103,376 @ $13.26 | EDGAR |
| 2025-03-11 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 95,399 @ $0 · Grant/award (A): 190,799 (derivative) @ $0 · Grant/award (A): 135,925 (derivative) @ $0 | EDGAR |
| 2024-12-26 | 4 | Evolus, Inc. (EOLS) | Sale (S): 10,502 @ $10.85 | EDGAR |
| 2024-12-17 | 4 | BIOMERICA INC (BMRA) | Grant/award (A): 85,000 @ $0.31 | EDGAR |
| 2024-06-06 | 4 | Evolus, Inc. (EOLS) | Sale (S): 140,214 @ $12.73 · Option exercise (M): 155,278 @ $5.46 · Sale (S): 155,278 @ $12.92 · Option exercise (M): 175,940 @ $7.28 · Sale (S): 175,940 @ $12.59 · Option exercise (M): 155,278 (derivative) @ $0 · +1 more | EDGAR |
| 2024-05-14 | 4 | Evolus, Inc. (EOLS) | Sale (S): 16,051 @ $12.72 | EDGAR |
| 2024-03-29 | 4 | Evolus, Inc. (EOLS) | Sale (S): 6,236 @ $13.86 | EDGAR |
| 2024-03-21 | 4 | Evolus, Inc. (EOLS) | Sale (S): 96,566 @ $13.92 | EDGAR |
| 2024-02-23 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 61,202 @ $0 · Sale (S): 7,706 @ $13.08 | EDGAR |
| 2024-02-09 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 134,976 @ $0 · Grant/award (A): 134,977 (derivative) @ $0 · Grant/award (A): 181,460 (derivative) @ $0 | EDGAR |
| 2023-12-14 | 4 | BIOMERICA INC (BMRA) | Grant/award (A): 75,000 (derivative) | EDGAR |
| 2023-12-11 | 4 | BIOMERICA INC (BMRA) | Grant/award (A): 25,000 (derivative) · Grant/award (A): 32,000 (derivative) | EDGAR |
| 2023-12-08 | 4 | Evolus, Inc. (EOLS) | Sale (S): 51,348 @ $10.09 · Sale (S): 31,300 @ $9.73 | EDGAR |
| 2023-08-16 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 91,803 @ $0 · Sale (S): 14,778 @ $10.27 | EDGAR |
| 2023-05-09 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 560,000 (derivative) @ $0 | EDGAR |
| 2023-03-29 | 4 | Evolus, Inc. (EOLS) | Sale (S): 6,110 @ $8.47 | EDGAR |
| 2023-03-16 | 4 | Evolus, Inc. (EOLS) | Sale (S): 64,211 @ $8.47 | EDGAR |
| 2023-01-27 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 187,927 @ $0 · Grant/award (A): 257,009 (derivative) @ $0 | EDGAR |
| 2022-05-18 | 4 | Evolus, Inc. (EOLS) | Sale (S): 55,321 @ $13.64 | EDGAR |
| 2022-03-30 | 4 | Evolus, Inc. (EOLS) | Sale (S): 6,104 @ $11.62 | EDGAR |
| 2022-03-10 | 4 | Evolus, Inc. (EOLS) | Sale (S): 37,972 @ $9.73 | EDGAR |
| 2022-01-26 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 214,286 @ $0 · Grant/award (A): 310,559 (derivative) @ $0 | EDGAR |
| 2021-08-17 | 4 | Evolus, Inc. (EOLS) | Sale (S): 22,708 @ $10.66 · Sale (S): 47,737 @ $11.35 | EDGAR |
| 2021-08-12 | 4/A | Evolus, Inc. (EOLS) | Sale (S): 41,763 @ $11.18 | EDGAR |
| 2021-08-12 | 4 | Evolus, Inc. (EOLS) | Sale (S): 41,763 @ $11.18 | EDGAR |
| 2021-03-26 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 48,853 @ $0 | EDGAR |
| 2021-02-01 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 266,667 @ $0 | EDGAR |
| 2021-01-26 | 4 | Evolus, Inc. (EOLS) | Sale (S): 8,310 @ $7.46 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-01-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1700836 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs